Journey Medical Corp
DERM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001867066
No open-market purchases or sales by Journey Medical Corp insiders were filed in the last 90 days; 71 institutions reported holding it in 13F filings for Q2 2026, worth $75.2M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Journey Medical Corp as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- 0 vs. Q4 2022
- Shares held
- 1.69M
- −114.0K (−6.3%) vs. Q4 2022
- Total value
- $2.62M
- −$851.4K (−24.5%) vs. Q4 2022
- New holders
- 1
- 3 more added
- Sold out
- 1
- 7 more reduced
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DERM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 71 | $75.2M |
| Q1 2026 | 72 | $55.8M |
| Q4 2025 | 77 | $85.0M |
| Q3 2025 | 68 | $61.9M |
| Q2 2025 | 56 | $46.6M |
| Q1 2025 | 38 | $29.6M |
| Q4 2024 | 37 | $14.8M |
| Q3 2024 | 36 | $12.2M |
| Q2 2024 | 35 | $13.3M |
| Q1 2024 | 33 | $6.68M |
| Q4 2023 | 36 | $7.80M |
| Q3 2023 | 21 | $5.85M |
| Q2 2023 | 20 | $2.63M |
| Q1 2023 | 17 | $2.62M |
| Q4 2022 | 18 | $5.13M |
| Q3 2022 | 20 | $4.62M |
| Q2 2022 | 13 | $6.52M |
| Q1 2022 | 14 | $7.94M |
| Q4 2021 | 14 | $8.76M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Journey Medical Corp; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| B. Riley Financial, Inc. | 774,796 | $1.22M | 0.32% | −89,899−10.4% | Reduced |
| Perkins Capital Management Inc | 218,395 | $343.0K | 0.32% | −7,405−3.3% | Reduced |
| Nantahala Capital Management, LLC | 212,357 | $333.4K | 0.03% | −13,639−6.0% | Reduced |
| American Financial Group Inc | 180,000 | $283.0K | 0.09% | 00.0% | Unchanged |
| Neuberger Berman Group LLC | 128,829 | $202.3K | 0.00% | −3,592−2.7% | Reduced |
| First Manhattan Co | 35,294 | $55.4K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 29,494 | $46.3K | 0.00% | −438−1.5% | Reduced |
| Vanguard Group Inc | 21,032 | $33.0K | 0.00% | +4,083+24.1% | Added |
| National Asset Management, Inc. | 17,250 | $27.1K | 0.00% | 00.0% | Unchanged |
| Creative Planning | 11,764 | $18.5K | 0.00% | 00.0% | Unchanged |
| Wealth Alliance Advisory Group, LLC | 10,748 | $16.9K | 0.01% | −5,376−33.3% | Reduced |
| Allegiance Financial Group Advisory Services LLC | 10,000 | $15.7K | 0.01% | 00.0% | Unchanged |
| BlackRock Inc. | 8,728 | $13.7K | 0.00% | +282+3.3% | Added |
| Tower Research Capital LLC (TRC) | 5,419 | $9.00K | 0.00% | −2,214−29.0% | Reduced |
| UBS Group AG | 4,198 | $6.59K | 0.00% | +4,198 | New |
| Wells Fargo & Company | 46 | $72 | 0.00% | +2+4.5% | Added |
| Cerity Partners LLC | 25,421 | – | – | 00.0% | Unchanged |
| Bank of America Corp | 0 | $0 | 0.00% | −14−100.0% | Sold out |
| B. Riley Securities, Inc. | – | – | – | – | Not filed |